4 completed. 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 4 |
Follow Filgotinib placebo: new trials by email Literature Review of Filgotinib placebo trials Research Report on Filgotinib placebo
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Evaluate the Safety and Efficacy of Filgotinib and Lanraplenib in Adults With Lupus Membranous Nephropathy (LMN) Filgotinib, Lanraplenib, Filgotinib placebo - Lupus Membranous Nephropathy | Phase 2 | Completed | Gilead Sciences | 9 | 2017-10-06 | 2020-05-18 |
| Study to Evaluate Safety and Efficacy of Filgotinib and Lanraplenib in Females With Moderately-to-Severely Active Cutaneous Lupus Erythematosus (CLE) Lanraplenib, Filgotinib, Lanraplenib placebo - Cutaneous Lupus Erythematosus | Phase 2 | Completed | Gilead Sciences | 47 | 2017-05-24 | 2020-06-09 |
| Study to Assess Safety and Efficacy of Filgotinib, Lanraplenib and Tirabrutinib in Adults With Active Sjogren's Syndrome Lanraplenib, Filgotinib, Tirabrutinib - Sjogren's Syndrome | Phase 2 | Completed | Gilead Sciences | 152 | 2017-05-01 | 2020-10-23 |
| Safety, Tolerability, and Efficacy of GS-9876 in Participants With Active Rheumatoid Arthritis on Background Therapy With Methotrexate GS-9876, Filgotinib, GS-9876 placebo - Rheumatoid Arthritis | Phase 2 | Completed | Gilead Sciences | 83 | 2016-09-21 | 2018-09-19 |
Arthritis, Rheumatoid (1) · Lupus Erythematosus, Cutaneous (1) · Sjogren's Syndrome (1)
Gilead Sciences (4)
United States (4) · Poland (2) · Bulgaria (1) · Canada (1) · Czechia (1) · Georgia (1) · Moldova (1) · Spain (1) · Ukraine (1) · United Kingdom (1)
PMID 33380521, PMID 34498056, PMID 35377447
2016 (2)